Further research revealed that NAT10 facilitates tumor progression and lymphangiogenesis in ccRCC by promoting the nuclear entry of the Yes1‐associated transcriptional regulator. This evidence concerns the gene NAT10 and nonpapillary renal cell carcinoma.